Conformis, Inc. Announces First Procedure Performed Using the Identity Imprint™ Knee Replacement System
August 18 2021 - 5:00PM
Conformis, Inc. (NASDAQ:CFMS) today announced the first
procedure with the new Conformis Identity Imprint knee replacement
system.
Identity Imprint, available in both cruciate retaining (CR) and
posterior stabilized (PS) implants, utilizes a proprietary
algorithm to select the implant size that most closely meets the
geometric and anatomic requirements of the patient’s knee based on
the individual’s CT scan. As with Conformis’ personalized iTotal®
knee product line, Identity Imprint uses Conformis’ sterile
Surgery-in-a-Box™ delivery system, which provides ambulatory
surgical centers (ASCs) and hospitals greater procedural efficiency
and improved sterilization cost savings over comparable
systems.
The first surgery was successfully performed by Dr. Moby Parsons
at Stratham Ambulatory Surgical Center in Stratham, New
Hampshire on August 16, 2021.
“I have long been an advocate of Conformis Image-to-Implant®
technology because I believe it consistently produces excellent
outcomes for patients,” said Dr. Parsons. “Identity Imprint is a
great option for those who elect not to wait for the production and
delivery of a personalized implant. This new system, which is
delivered in about three weeks, helps surgeons optimize implant
placement with its iView® pre-operative surgical plan and
patient-specific, 3D-printed, single-use iJig® surgical
instruments.”
With the number of knee procedures to be performed in ASCs and
outpatient settings expected to grow significantly, Identity
Imprint is an efficient and cost-effective option for those who
want to combine traditional lead times and intraoperative
flexibility with the benefits of the Surgery-in-a-Box model.
“Identity Imprint integrates elements of personalized design
with the convenience and flexibility of an off-the-shelf system,
which is advantageous for surgeons and patients alike,” said Mark
Augusti, President and CEO of Conformis. “We are already an
industry leader with delivery model efficiencies and sterilization
savings. By adding Imprint, we believe that we have the best
portfolio to address changing customer needs and current market
dynamics.”
The global knee joint reconstruction market is projected at
over $9 billion, with approximately 1 million knee
replacements expected to be performed in the United
States this year.
About Conformis, Inc.
Conformis is a medical technology company that uses its
proprietary iFit® Image-to-Implant® technology platform to develop,
manufacture, and sell joint replacement implants and instruments
that are individually sized and shaped, which we refer to as
personalized, individualized, or sometimes as customized, to fit
and conform to each patient’s unique
anatomy. Conformis offers a broad line of sterile,
personalized knee and hip implants and standard implants, along
with single-use instruments delivered to hospitals and ambulatory
surgical centers. In clinical studies,
the Conformis iTotal® CR knee replacement system
demonstrated superior clinical outcomes, including better function
and greater patient satisfaction, compared to traditional,
off-the-shelf implants. Conformis owns or exclusively
in-licenses issued patents and pending patent applications that
cover personalized implants and patient-specific instrumentation
for all major joints.
For more information, visit www.conformis.com. To receive
future releases in e-mail alerts, sign up
at http://ir.conformis.com.
Cautionary Statement Regarding Forward-Looking
Statements
Statements in this press release about our future expectations,
plans and prospects, as well as other statements containing the
words “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,”
“project,” “should,” “target,” “will,” or “would” and similar
expressions, constitute forward-looking statements within the
meaning of the safe harbor provisions of The Private Securities
Litigation Reform Act of 1995. You should not place undue reliance
on our forward-looking statements. Actual results could differ
materially from the projections disclosed in the forward-looking
statements we make as a result of a variety of risks and
uncertainties, including risks and uncertainties described in the
“Risk Factors” sections of our public filings with
the Securities and Exchange Commission. In addition, the
forward-looking statements included in this press release represent
our views as of the date hereof. We anticipate that subsequent
events and developments may cause our views to change. However,
while we may elect to update these forward-looking statements at
some point in the future, we specifically disclaim any obligation
to do so. These forward-looking statements should not be relied
upon as representing our views as of any date subsequent to the
date hereof.
Source: Conformis, Inc.
Media Contact:
Investor Relations
ir@conformis.com
(781) 374-5598
Conformis (NASDAQ:CFMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Conformis (NASDAQ:CFMS)
Historical Stock Chart
From Apr 2023 to Apr 2024